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Abstract
The efficacy of cancer immunotherapy, including treatment with immune-checkpoint inhibitors, often is limited by ineffec-
tive presentation of antigenic peptides that elicit T-cell-mediated anti-tumor cytotoxic responses. Manipulation of antigen 
presentation pathways is an emerging approach for enhancing the immunogenicity of tumors in immunotherapy settings. 
ER aminopeptidase 1 (ERAP1) is an intracellular enzyme that trims peptides as part of the system that generates peptides 
for binding to MHC class I molecules (MHC-I). We hypothesized that pharmacological inhibition of ERAP1 in cells could 
regulate the cellular immunopeptidome. To test this hypothesis, we treated A375 melanoma cells with a recently developed 
potent ERAP1 inhibitor and analyzed the presented MHC-I peptide repertoire by isolating MHC-I, eluting bound peptides, 
and identifying them using capillary chromatography and tandem mass spectrometry (LC-MS/MS). Although the inhibitor 
did not reduce cell-surface MHC-I expression, it induced qualitative and quantitative changes in the presented peptidomes. 
Specifically, inhibitor treatment altered presentation of about half of the total 3204 identified peptides, including about one 
third of the peptides predicted to bind tightly to MHC-I. Inhibitor treatment altered the length distribution of eluted peptides 
without change in the basic binding motifs. Surprisingly, inhibitor treatment enhanced the average predicted MHC-I binding 
affinity, by reducing presentation of sub-optimal long peptides and increasing presentation of many high-affinity 9–12mers, 
suggesting that baseline ERAP1 activity in this cell line is destructive for many potential epitopes. Our results suggest that 
chemical inhibition of ERAP1 may be a viable approach for manipulating the immunopeptidome of cancer.
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Introduction
Immunotherapy using immune-checkpoint inhibitors is 
rapidly changing the landscape of cancer treatment [1]. 
Despite often impressive clinical results using this approach, 
the therapeutic benefit appears to be limited to a subset of 
patients. Several ongoing research efforts aim to enhance 
anti-cancer immune responses by potentiating the effects 
of immune-checkpoint inhibitors using complementary 
approaches. Recent analyses have revealed that the potency 
of immune-checkpoint inhibitor therapies depends largely 
on the generation of cancer-specific antigens by cancer cells 
[2, 3]. Furthermore, presentation of cancer-specific antigens 
is a major predictor of long-term survival in cancer patients 
[4]. Cancer-specific antigens can be detected by cytotoxic 
T lymphocytes, which recognize peptidic fragments (anti-
genic peptides) generated by proteolytic processing of cel-
lular proteins that are loaded onto major histocompatibility 
class I molecules (MHC-I) and presented on the cell surface. 
Cytotoxic T lymphocytes play an important role in the con-
trol and progression of cancer by mounting strong cytotoxic 
responses against transformed or malignant cells. During the 
process of cancer immunoediting [5], cancer cells undergo 
selection which enables them to avoid adaptive immune 
responses and allows them to proliferate in immune-com-
petent hosts. Strategies used by cancer cells to evade the 
immune response involve modulation of key immune path-
ways such as the expression of cell-surface inhibitory recep-
tors and the destruction of key antigenic peptides [6, 7]. This 
notion was recently strengthened by two studies demonstrat-
ing that the CD28/B7 co-stimulatory pathway, a signaling 
interaction that is necessary for correct antigenic peptide 
recognition, is critical to the efficacy of anti-PD-1 therapy 
[8, 9]. Furthermore, in a recent study using CRISPR–Cas9 
genome editing in transplantable tumors in mice, several 
genes in the antigen processing and presentation pathway 
were shown to be able to sensitize tumors to PD-1 check-
point blockade immunotherapy [10].
Although the generation and identification of particular 
cancer-specific antigenic epitopes often is the focus of can-
cer immunotherapy research, global “antigenic signature” 
shifts in cancer cells have been proposed to be a more reli-
able predictor of the efficacy of adaptive immune responses 
against cancer. In a recent study of human gastrointestinal 
cancers, strong immune responses against particular neo-
epitopes were observed despite the fact that these epitopes 
were not shared between patients [11]. Similarly, a recent 
study on metastatic melanoma showed a strong correlation 
between the clinical outcome of treatment with a monoclonal 
antibody against the immune-checkpoint receptor CTLA-4 
and the mutational and neoantigen load of the cancer cells, 
although no recurrent cancer-specific epitopes were found 
amongst patients [2]. These studies suggest that the pres-
entation of novel cancer antigens is critical for robust anti-
cancer immune responses, although the particular epitopes 
that induce such responses may vary significantly between 
individuals and are difficult to predict.
Antigenic peptides presented by MHC-I are generated 
inside the cell by complex proteolytic pathways that often 
begin with the degradation of intracellular proteins by the 
proteasome (or immunoproteasome) and end with the trim-
ming of excess N-terminal amino acids by aminopepti-
dases [12]. During the last decade, the important role of 
endoplasmic reticulum (ER) aminopeptidases in generating 
antigenic peptides for MHC-I has become clearer [13, 14]. 
ER aminopeptidase 1 (ERAP1) processes antigenic peptide 
precursors to generate mature antigenic peptides of the cor-
rect length for binding onto MHC-I (usually 8–10 amino 
acids long) [15, 16]. A highly homologous aminopeptidase, 
endoplasmic reticulum aminopeptidase 2 (ERAP2), can sup-
plement ERAP1 activity in generating antigenic peptides, 
but plays a secondary accessory role [17]. In addition to its 
role in generating antigenic peptides, several studies have 
found that ERAP1 can also destroy antigenic peptides by 
trimming them to lengths too short to bind to MHC-I [18]. 
Genetic down-regulation of ERAP1 has been shown to have 
significant impact on both the nature of antigenic peptides 
presented on the cell surface and on concomitant cytotoxic 
responses [19–25]. To this extent, ERAP1 has been sug-
gested to be a potent editor of both the immunopeptidome, 
the set of peptides presented by MHC molecules, and of the 
immunodominance hierarchy, the pattern of T-cell responses 
to these peptides [20, 26].
ERAP1 is polymorphic in the human population. Many 
GWAS and targeted population studies have associated cod-
ing SNPs in ERAP1 with predisposition to disease, including 
autoimmunity, viral infection, and cancer [27, 28]. The link 
to autoimmunity has been repeatedly confirmed and ERAP1 
SNPs are found to be in epistasis with disease-specific HLA 
[29, 30]. ERAP1 SNPs have also been associated with other 
major human diseases, including cancer, most notably with 
the clinical outcome in cervical carcinoma [31]. Several 
in vitro and cell-based studies have validated the functional 
association between ERAP1 and disease, and have demon-
strated that ERAP1 allelic state affects enzymatic activity 
and the capacity to generate and/or destroy antigenic pep-
tides [32–34]. It is becoming established that the genetic 
variability in ERAP1 confers a functional range of enzy-
matic activities and contributes to the variability of immune 
responses between individuals [35]. ERAP1 expression has 
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been targeted by pathogens as an immune evasion measure: 
human cytomegalovirus produces a microRNA that down-
regulates ERAP1 expression by about 50%, modulating 
CTL responses to infected cells by reducing the generation 
of ERAP1-dependent antigenic epitopes [36]. Cancerous 
tumours of different origins can either down-regulate or 
up-regulate ERAP1, presumably as part of cancer immune-
editing processes [37, 38]. Interestingly, many cancers were 
found to up-regulate ERAP1. In model systems, ERAP1 has 
been shown to destroy tumour-associated antigenic peptides 
[22, 39], suggesting that tumour antigen destruction may 
constitute an immune-evading strategy for some cancers. 
Furthermore, down-regulation of ERAP1 activity has been 
shown to increase CTL and NK responses towards cancer 
cells, and to suppress autoimmune cytotoxic responses [21, 
22, 40, 41]. In a recent CRISPR–Cas9 genome editing study, 
ERAP1 was one of the genes demonstrated to be able to 
sensitize melanoma tumors to PD-1 immunotherapy [10]. 
Thus, ERAP1 pharmacological inhibition in such tumours 
may have therapeutic value [42].
We have developed a potent ERAP1 inhibitor, DG013A, 
by structure-guided design based on key features of the 
ERAP1 active site, and shown that it can affect the presen-
tation of specific antigens in cells and can reprogram antigen 
processing to elicit CTL responses against a cryptic epitope 
in a murine colon carcinoma model [43]. Recently, the same 
inhibitor has been used to down-regulate ERAP1-dependent 
innate immune responses such as activation of macrophage 
phagocytosis and NK cell activation after LPS treatment, 
and to suppress ERAP1-dependent Th17 responses in vitro 
[44, 45]. In this study, we set to examine the effects of this 
inhibitor on the global immunopeptidome of a melanoma 
cell line to test the hypothesis that ERAP1 inhibition can 
induce significant changes on the cellular immunopepti-
dome. This approach potentially could be utilized pharma-
cologically in the context of immunotherapy to induce robust 




Cells were cultured in DMEM containing stable glutamine, 
supplemented with 10% heat-inactivated FBS (Gibco), peni-
cillin and streptomycin and incubated at 37 °C, 5%  CO2.
Antibodies
For the immunopurification of the MHC-I molecules carry-
ing the A375 peptidome, the W6/32 monoclonal antibody 
was used. The antibody was isolated from hybridoma cell 
culture supernatant and purified using protein G affinity 
chromatography. For FACS analysis, MHC-I molecules 
were stained with the W6/32 monoclonal antibody conju-
gated with FITC (Biorad, MCA81F). ERAP1 was detected 
in cell lysates using aminopeptidase PILS/ARTS1 anti-
body 6h9 (mab2334) and human aminopeptidase PILS/
ARTS1 polyclonal goat IgG (R&D Systems, AF2334) as 
primary antibodies. ERAP2 western blots were performed 
using the Human ERAP2 polyclonal goat IgG (R&D Sys-
tems, AF3830). Anti-mouse IgG–HRP (HAF007) and anti-
goat IgG–HRP (HAF017) were also purchased from R&D 
systems.
Recombinant proteins and enzymatic assays
Recombinant ERAP1 was produced from baculovirus-
infected insect cells (Hi5™) as described previously [46]. 
Enzymatic titrations to evaluate the in vitro efficacy of the 
inhibitor were performed using a small fluorescent substrate 
assay as described previously [47].
Western blotting and genotyping
About 5 × 105 A375 cells were lysed with 500  μl lysis 
buffer containing 1% NP-40, 0.25% sodium deoxycholate, 
1 mM EDTA, pH 8.0, complete protease inhibitors (Roche: 
12326400) in 50 mM Tris–HCl, pH 7.5, and 150 mM NaCl 
buffer. After cell lysis, the total protein concentration was 
determined using bicinchoninic acid (BCA) Protein Assay 
Kit (Thermo Scientific, 23250). Whole cell lysates were 
analyzed with SDS-PAGE under reducing conditions in a 
10% polyacrylamide gel. Equal amounts of total protein 
were loaded in each lane, based on BCA assay. The sepa-
rated proteins were blotted onto a polyvinylidene difluoride 
(PVDF) membrane (Thermo Scientific, 88520) using the 
antibodies described above. Primary antibodies were used 
at a final concentration 2 μg/ml and the secondary antibodies 
were diluted 1:1000. As an HRP substrate, we used Pierce 
chemiluminescent western blotting substrate (Thermo scien-
tific, 32209) and enhanced chemiluminescence was detected 
in LAS 4000 (Fujifilm). The images were processed using 
AIDA Image analyzing software. A375 cells were geno-
typed to determine which HLA alleles they expressed by 
the Center for Human Genetics and Laboratory Diagnostics, 
Dr. Klein, Dr. Rost and Colleagues, Ambulatory Healthcare 
Center, 82152 Martinsried-Germany. The anchor residues 
of the identified HLA molecules were determined based on 
the information derived from SYFPEITHI database (http://
www.syfpe ithi.de/) and in the case of HLA-C*16:01 from 
The HLA FactsBook (D. Barber, Peter Parham, and Steven 
Marsh).
To determine the ERAP1 SNPs carried by A375 cells, 
10 million cells were washed twice with ice-cold PBS and 
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incubated overnight at 37 °C with lysis buffer (10 mM 
NaCl, 10 mM Tris–HCl pH 7.5, 10 mM EDTA, 0.5% 
SDS and 100 μg/ml RNAse A and 100 μg/ml protein-
ase K). Genomic DNA was isolated by phenol/CHCl3 
extraction and precipitated with 1/10 vol of 3 M sodium 
acetate, pH 5.2, and 2 vol of 100% ethanol. The pellet 
was washed with 70% ethanol, re-suspended in sterile 
deionized distilled  H2O and quantitated by absorbance 
at 260 nm. 50 ng of each DNA sample was used as tem-
plate for conventional PCR. Forward and reverse prim-
ers used for exons 11, 12 and 15 are 5′-AAA TGG GTG 
ATG TGT CTG CC-3′ and 5′-TCA AAA GCA AGG TTC CAT 
CC-3′, 5′-CAT GAT AGG TGA TTT AAT AAC TGC TTG-3′ 
and 5′-TTT TCA CAT TCC TCC TTG AAT TAA C-3′, 5′-TAC 
TGG TCC CTG TTT CCC TG-3′ and 5′-AAA CAG AAA AGA 
TGC CCT TCAC-3′, respectively. The PCR products were 
isolated and sequenced using both the forward and reverse 
primers.
Synthesis of phosphinic inhibitor DG013A
The synthesis of phosphinic pseudotripeptide DG013A 
[43] started from the stereochemically pure building block 
Cbz-(R)-hPhe[PO(OH)CH2](S)-Leu-OH (the preparation 
of this precursor will be reported elsewhere). Removal of 
the amino terminal Cbz-protecting group was performed 
in acidic conditions using HBr/AcOH as a deprotection 
medium. The hydrobromic salt of the resulting pseudodi-
peptide was protected with the Boc group under basic 
conditions using (Boc)2O as a protection reagent. This 
procedure afforded the building block of the formula 
Boc-(R)-hPhe[PO(OH)CH2](S)-Leu-OH in 83% overall 
yield, starting from the Cbz-protected analog [48]. Cou-
pling of H-(S)Trp-NH2 followed a previously reported 
protocol which allows efficient peptide coupling in the 
presence of an unprotected phosphinic acid group [49]. 
In particular, excess of N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride was employed as a cou-
pling reagent, in the presence of hydroxybenzotriazole 
and N,N-diisopropylethylamine. Purification of the result-
ing Boc-protected tripeptide and subsequent standard 
acidic deprotection by dilute trifluoroacetic acid afforded 
DG013A in 75% yield for the last two synthetic steps. 
The compound was purified by reversed-phase HPLC 
on a C18 chromolith column (Merck) using a 10–50% 
(vol/vol) acetonitrile gradient in water containing 0.05% 
(vol/vol) trifluoroacetic acid. A single major peak was 
characterized by mass spectrometry, lyophilized, and dis-
solved in deionized water. The inhibitor concentration in 
the final working stock was calculated using the meas-
ured absorbance at 280 nm and the extinction coefficient 
5700 M−1 cm−1.
Cytotoxicity MTT assay
A375 cells (5000 cells/well) were cultured as described 
above in the presence of varying concentrations of DG013A 
(0–30 μM) for 48 h. The culture medium was replaced by 
100 μl of DMEM containing 1 mg/ml MTT reagent. After 
incubation for another 4 h, the resultant formazan crystals 
were dissolved in DMSO (100 μl) and the absorbance inten-
sity was measured on a TECAN infinite M200 microplate 
fluorescence reader at 540 nm with reference at 620 nm. All 
experiments were performed at least three times and the rela-
tive cell viability (%) was expressed as a percentage relative 
to untreated control cells.
A375 treatment with DG013A inhibitor
A375 cells were treated with DG013A inhibitor for a total 
of 6 days. The inhibitor was added to the complete culture 
medium at a final concentration 1 μM. The cell medium that 
contained the inhibitor was refreshed every 2 days. Cell cul-
tures were incubated as usual at 37 °C, 5%  CO2. After 6 days 
of incubation, cells were harvested for immunopeptidome 
isolation or for flow cytometry. For immunopeptidome anal-
ysis, cells were cultured at a large scale and collected from 
flasks using accutase solution (Merck SCR005). Cell pellets 
were stored at − 80 °C until immunopeptidome isolation. For 
the flow cytometry analysis, cells were seeded in a 12-well 
plate and harvested with 10 mM EDTA, pH 8.0, in PBS.
Flow cytometry
Approximately 1 × 106 cells per sample were transferred in 
FACS tubes after harvesting, and were washed twice with 
1 ml FACS buffer (1%BSA/PBS, 0.02%  NaN3). The cells 
were stained with 2 μl undiluted W6/32-FITC for 30 min on 
ice. After incubation, the cells were washed with 2 ml FACS 
buffer, centrifuged at 200g for 5 min at 4 °C and re-sus-
pended in 300 μl FACS buffer. The samples were analyzed 
in a FACScalibur flow cytometer using the BD CellQuest™ 
Pro software. Approximately 20,000 events per sample were 
measured.
Preparation of immunoaffinity columns
W6/32 antibody (2 mg per column) was dialyzed in coupling 
buffer  (NaHCO3 0.1 M, NaCl 0.5 M, pH 8.3) overnight. To 
generate one 1 ml bed volume of cyanogen bromide-acti-
vated Sepharose 4B (GE Healthcare 17-0430-01), 0.285 g 
of dry beads was used. Sepharose was rehydrated with 1 mM 
HCl for 30 min and then washed thoroughly with coupling 
buffer. The solution of the antibody was added to the beads 
and left for coupling overnight at 4 °C. After coupling, 
the beads were washed with coupling buffer and then with 
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blocking buffer (Tris–HCl 0.1 M, pH 8.0). After the washes 
the beads were transferred to a 50-ml tube with blocking 
buffer and were mixed for 3 h at room temperature. Finally, 
the beads were washed with three cycles of acidic buffer 
 (CH3COONa 0.1 M, NaCl 0.5 M, pH 4.0) and then basic 
buffer (Tris–HCl 0.1 M, NaCl 0.5 M, pH 8.0) solutions and 
then with 20 mM Tris–HCl, pH 7.5, 150 mM NaCl. For the 
pre-columns, the exact same procedure was followed with 
the exception of the W6/32 coupling step. The columns and 
the pre-columns were stored at 4 °C until needed.
Isolation of MHC‑I immunopeptidome
For the isolation of the immunopeptidome, 5 × 108 cells per 
sample were used. Cells were lysed with 20 ml lysis buffer 
(Tris–HCl, pH 7.5, 150 mM NaCl, 0.5% IGEPAL CA-630, 
0.25% sodium deoxycholate, 1 mM EDTA, pH 8.0, 1 × com-
plete EDTA-free protease inhibitor cocktail tablets) for 1 h 
at 4 °C. The cell lysate was cleared with ultracentrifugation 
at 100000 g for 1 h at 4 °C and then loaded onto a cyano-
gen bromide-activated Sepharose pre-column, blocked as 
described above. The flow through from the pre-column 
was passed through W6/32-coupled beads three times and 
then washed with 20 bed volumes 20 mM Tris–HCl, pH 
8.0, 150 mM NaCl, 20 bed volumes 20 mM Tris–HCl, pH 
8.0, 400 mM NaCl, 20 bed volumes 20 mM Tris–HCl, pH 
8.0, 150 mM NaCl and finally with 40 bed volumes 20 mM 
Tris–HCl, pH 8.0. The MHC-I–peptide complexes were 
eluted from the immunoaffinity column with 1% TFA. The 
peptides were separated from the MHC-I molecules using 
reversed-phase C18 disposable spin columns (Thermo Sci-
entific). The fraction containing peptides was dried prior to 
LC-MS/MS analysis.
Mass spectrometry analysis
Each sample was analyzed in a Q-Exactive-Plus mass spec-
trometer (Thermo Fisher Scientific) as described previously 
[50]. Peptides were separated using a 7–40% acetonitrile 
gradient with 0.1% formic acid for 180 min and a flow rate of 
0.15 l/min on a 0.075-mm × 30-cm capillary column packed 
with Reprosil C18-Aqua (Dr. Maisch, GmbH, Ammerbuch-
Entringen, Germany). The dynamic exclusion was set to 
20 s. Selected masses were fragmented from the survey scan 
of mass to charge ratio (m/z) 300–1800 atomic mass units 
at resolution of 70,000. MS/MS spectra were acquired start-
ing at m/z 200 with a resolution of 17,500. The target value 
was 1 × 105, and the isolation window was 1.8 Da. Peptide 
sequences were assigned from the MS/MS spectra using the 
Max-Quant software (version 1.5.0.25) [51] and the human 
UniProt/Swiss-Prot database (release 2015_07: 69,693 
entries). Precursor ion mass and fragment mass tolerance 
was set to 20 ppm, FDR was set to 0.01, peptide-spectrum 
matching FDR to 0.05 and oxidation (Met), acetyl (protein 
N terminus), and Gln to Pyro-Glu were used as variable 
modifications. Any identification from the reverse database 
and known contaminants were eliminated.
Cellular antigen processing assay
HeLa cells stably expressing H-2 Kb [18] were plated in 
24-well plates and infected with recombinant vaccinia which 
expresses signal sequence—LEQLESIINFEKL–IRES–GFP. 
At the time of infection, DG013A or leucinethiol were also 
added to the cells. All conditions contained 0.5% DMSO. 
After 18–22 h, the cells were incubated with 25.D1.16 mon-
oclonal mouse antibody, which specifically recognizes the 
SIINFEKL:H-2 Kb peptide MHC complex [52]. After incu-
bating 30 min on ice, the cells were washed with Dulbecco’s 
PBS and Alexa647-goat anti-mouse antibody was added to 
the cells at 1:200 (v/v) dilution. After incubating 30 min on 
ice, the cells were washed with Dulbecco’s PBS. The cells 
were then re-suspended in 250 μl Dulbecco’s PBS and fixed 
by addition of 250 μL 4% formalin in Dulbecco’s PBS (v/v) 
for 15 min at room temperature. The fixation was stopped 
with the addition of 250 μl Dulbecco’s PBS supplemented 
with 1% (v/v) fetal bovine serum and 0.01% (m/v) sodium 
azide. Sample GFP and Alexa 647 fluorescence was meas-
ured using a LSR-II and analyzed using the FlowJo 9.6.4 
software. Singlets were identified by comparing forward 
scatter signal height and width, and then GFP-positive sam-
ples were identified by comparison to an uninfected control. 
Alexa 647 median fluorescence intensity was normalized 
where MFI of a sample without inhibitor treatment is set 
to one, and the MFI of a sample treated with 100 μM leu-
cinethiol is set to zero. Calculation of  IC50 was performed 
using Prism 6.
Results
The ERAP1 inhibitor DG013A can regulate 
the presentation of an ERAP1‑dependent antigenic 
model epitope
To inhibit ERAP1 in A375 cells, we used the inhibitor 
DG013A, which is, to our knowledge, the most potent 
ERAP1 inhibitor reported to date (Fig. 1a) [43]. The inhibi-
tor was synthesized using stereoselective synthesis as 
described in the experimental section and in [47]. To vali-
date the ability of the inhibitor to inhibit ERAP1 in vitro, 
we performed an enzymatic titration that indicated a half-
maximum inhibitory concentration of 43.5 ± 2.5 nM, which 
is consistent with previously published values (Fig. 1a).
To help establish a minimum dosage of the inhibi-
tor sufficient to regulate the MHC-I presentation of 
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ERAP1-dependent epitopes, we utilized a cellular assay 
that follows the presentation of the ovalbumin epitope SIIN-
FEKL, a well-characterized epitope that requires ERAP1 
for presentation [18]. A HeLa cell line stably transfected to 
express mouse H2-Kb was infected with a vaccinia virus that 
targets the epitope precursor with the sequence LEQLESI-
INFEKL to the ER. Normally, ERAP1 processing can gener-
ate the mature epitope SIINFEKL, which when loaded onto 
H2-Kb is transferred to the cell surface and can be detected 
by a specialized monoclonal antibody [18]. Titration of 
increasing concentrations of DG013A resulted in a dose-
dependent reduction of  Kb-SIINFEKL on the cell surface 
with an apparent  ED50 of 350 ± 160 nM (Fig. 1c). This find-
ing further validated the ability of this compound to affect 
ERAP1-dependent antigen presentation in cells and estab-
lished that using 1μΜ inhibitor in the cell medium should be 
sufficient to substantially inhibit ERAP1 in cells.
Characterization of the A375 melanoma cell line 
as an appropriate template to study the regulation 
of immunopeptidome by ERAP1
To gain insight into the effects of ERAP1 inhibition on the 
global immunopeptidome of human cells, we selected the 
A375 cell line, which has been established from malignant 
melanoma skin tumors. The inhibitor does not appear to be 
toxic to A375 cells up to a concentration of 30 μM, as judged 
by the MTT assay (Supplemental Figure 1). Genotyping 
for HLA-type revealed that A375 cells carry six MHC-I 
alleles, namely HLA-A*01:01:01, HLA-A*02:01:01, HLA-
B*44:03:01, HLA-B*57:01:01, HLA-C*06:02:01 and HLA-
C*16:01:01. Based on peptide presentation data from the 
SYFPEITHI database [53], we also noted the expected 
anchor residue positions in each allele (Supplemental Figure 
S2a). Using the W6/32 antibody, which can detect all human 
MHC class I alleles, we compared cell-surface staining on 
A375 cells by FACS (Supplemental Figure S2b). No signifi-
cant change in MHC-I levels on the surface of A375 cells 
was evident when the cells were exposed to 1 μM DG013A 
for up to 6 days, suggesting that chemical inhibition of 
ERAP1 was not sufficient to produce any long-term effects 
on the overall MHC-I expression at the cell surface. This is 
consistent with a recent study that compared the effect of 
ERAP1 shRNA down-regulation on MHC-I surface expres-
sion in other cancer cell lines [41], and knockout of ERAP1 
in transgenic HLA-B27 rats [25]. ERAP1 expression in 
A375 cells was validated by western blot (Supplemental Fig-
ure 2c) and found to be up-regulated by interferon-gamma, 
consistent with the published literature [41, 54]. We com-
pared ERAP1 levels in the cells to the homologous ERAP2, 
given that DG013A also inhibits that enzyme. According to 
the EMBL Expression Atlas database, A375 cells express 
72 transcripts per kilobase million ERAP1 RNA, but only 2 
transcripts per kilobase million ERAP2 RNA [55]. Accord-
ingly, comparing western blot signals to recombinant con-
trols revealed that ERAP2 protein is expressed at least ten-
fold less than ERAP1 (Supplemental Figure S3). Thus, we 
expect ERAP1 activity to be dominant compared to ERAP2 
Fig. 1  Compound DG013A inhibits ERAP1 in vitro and can inhibit 
presentation of an ERAP1-dependent antigenic peptide by cells. a 
Chemical structure of inhibitor DG013A. b Titration of DG013A 
inhibits recombinant ERAP1 activity in vitro. c Titration of DG013A 
to HeLa:Kb cells infected with vaccinia virus that targets an N-termi-
nally extended precursor of the SIINFEKL epitope to the ER leads to 
a dose-dependent reduction in surface presentation of the epitope
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in antigen processing in A375 cells. Since ERAP1 SNPs 
have been shown to affect enzymatic activity and to alter 
the cellular immunopeptidome, we determined the ERAP1 
allelic composition in A375 cells. This was done by genomic 
sequencing of exons 11, 12 and 15 of the ERAP1 gene since 
these exons harbor four common coding single nucleotide 
polymorphisms that have been most commonly associated 
with disease and functional changes [27, 28, 32]. According 
to sequencing results (Supplemental Figure S4), ERAP1 in 
A375 cells carries SNPs 528 K, 575D, 725R, 730Q, which 
correspond to the ancestral haplotype [56]. Interestingly, 
several studies have associated SNPs 528 K and 730Q with 
a higher enzymatic activity, suggesting that A375 cells carry 
a highly active ERAP1 allele [30, 32, 33].
Analysis of A375 immunopeptidome by capillary 
chromatography and tandem mass spectrometry
Since the inhibitor does not appear to influence cell-
surface MHC-I levels but can affect the presentation of a 
model epitope, we set forth to evaluate its effects on the 
peptide repertoire presented by the natural MHC alleles 
in A375 cells. Towards this end, we purified MHC-I–pep-
tide complexes from A375 cells that had been exposed 
to 1 μM DG013A for 6 days. A control experiment was 
performed in the absence of the inhibitor. A375 cells were 
solubilized in mild detergent and MHC-I–peptide com-
plexes were purified by affinity chromatography using 
immobilized W6/32 antibody. MHC-I-bound peptides 
were eluted by acid extraction and analyzed by LC-MS/
MS. To have sufficient statistical power to define the inhib-
itor-induced changes, we performed three biological rep-
licates for each condition. A MaxQuant-style table listing 
all identified peptides can be freely downloaded at https 
://sfile r.ipta.demok ritos .gr/s/qMJGB CCE6o Sqi5p (pass-
word erap1a375). The cross-correlation analysis revealed 
good correlation between same condition replicates and a 
weaker correlation between cross pairs (inhibitor versus 
control)(Fig. 2). Both control and inhibitor samples con-
tained many peptide sequences unique to the respective 
condition (Fig. 3a, boxes [a] and [b]). However, several 
peptides present in both conditions were detected with 
intensities that were statistically different (Fig. 3b). Thus, 
in accordance with a previous study [57], we defined 
peptides to be control-specific when they were either 
uniquely identified in the control condition or down-reg-
ulated by the inhibitor by at least fourfold (Fig. 3b, box 
labeled “Control”). Similarly, we defined peptides as 
Fig. 2  Treating A375 cells with the inhibitor affects global presenta-
tion by MHC-I. a Correlations in peptide intensity between different 
experiments or replicates. The calculated Pearson coefficient is indi-
cated in each panel. b Average Pearson coefficient of correlations 
between control replicates, inhibitor replicates, and control versus 
inhibitor experiments. c Average Pearson coefficient of correlations 
between replicates of the same condition and control versus inhibitor
1252 Cancer Immunology, Immunotherapy (2019) 68:1245–1261
1 3
inhibitor-specific when they were either uniquely identi-
fied in the inhibitor condition or up-regulated by the inhib-
itor by at least fourfold (Fig. 3b, box labeled “Inhibitor”). 
We defined as “common” the peptides that were common 
in both conditions with a less than fourfold difference in 
intensities between the control and inhibitor condition. 
Thus, we assigned 1589 peptides to be common, 1198 
to be control-specific and 417 to be inhibitor-specific. 
Since there is an established association between affin-
ity of a peptide ligand for MHC-I and immunogenicity 
[58, 59], we scored each identified peptide for predicted 
affinity versus the HLA alleles carried by A375 using the 
NetMHCcons1.1 server [60] (Fig. 3c). Based on previ-
ous studies [58, 59], 90% of all epitopes have an affin-
ity for MHC-I below 1μΜ and thus we used this value 
as cut-off (Fig. 3c, boxed region). This analysis revealed 
that 38% of all identified peptides are predicted to be very 
weak MHC-I binders (predicted affinity > 1 μM). This set 
will include true MHC-I ligands with high affinity that 
are incorrectly predicted, true but weakly binding MHC-I 
ligands that are unlikely to be immunogenic, and non-
binding contaminant peptides. Of the remaining 62% of 
peptides predicted to be good MHC-I binders, 1247 pep-
tides were common to both conditions, 458 peptides were 
control-specific and 333 peptides were inhibitor-specific 
(Fig. 3d). To detect if any neoantigens were presented by 
A375 cells in our experiment, we identified 505 known 
coding mutations present in A375 cells and deposited in 
the Cancer Cell Line Encyclopedia [61], and searched for 
eluted peptides carrying at least one of those mutations. 
Only a single peptide carrying a neoantigen mutation was 
identified, namely peptide GLLPNIQAV from HIST3H2A 
(ENST00000366695) that carries the mutation V108L (in 
bold in peptide sequence), which is predicted to be a very 
good (8.9 nM) binder for HLA-A02:01. This single neoan-
tigen-derived peptide, however, was present in all experi-
ments regardless of inhibitor treatment suggesting it is not 
ERAP1 dependent. Overall, our results demonstrate that 
Fig. 3  Statistical analysis of inhibitor effects on presented peptides. a 
Scatter plot of the average intensities along three biological replicates 
of identified peptides, colored by length. Each circle corresponds to 
a unique peptide sequence. Peptides identified in only one condition 
were assigned intensities at the threshold of detection for the other 
condition (boxes a, b). Peptides identified in both conditions are in 
box c. Color coding indicates peptide length. b Volcano plot showing 
peptides that are either up-regulated or down-regulated by the inhibi-
tor. Peptides within the two square areas are affected in a statistically 
significant manner by more than fourfold and were classified to be 
specific to each respective condition. c Predicted affinity of peptides 
for MHC-I alleles expressed in A375 cells, as calculated by the Net-
MHCcons1.1 server [60]. Affinities were calculated for each peptide 
for all six HLA-alleles carried by A375 cells, but only the best affin-
ity was plotted. The boxed region indicates peptides that are predicted 
to bind to at least one MHC-I allele with an IC50 value below 1 μΜ. 
d Numbers of peptides assigned to each condition
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incubating A375 cells with the ERAP1 inhibitor DG013A 
induces a significant shift in the peptides that are presented 
by MHC-I but this shift is limited to about one third of the 
cellular immunopeptidome. 
Effects on presented peptide length and predicted 
affinity
Length is an important parameter that influences peptide 
binding and presentation by MHC-I, thus we analyzed the 
effect of the inhibitor on the length of presented peptides 
(Fig. 4). In all cases, most of the peptides presented were 
9mers, consistent with the optimal length for MHC-I bind-
ing and with the fact that the majority of known antigenic 
peptides are 9mers. Amongst all peptides identified, the 
inhibitor-specific group had a larger percentage of 9mers 
compared to the control-specific group (Fig. 4a), as well as 
a larger percentage of 10mers and 11mers. This trend was 
reversed, for larger peptides, with the control group con-
taining a larger percentage of 12–16mers. When limiting 
the analysis to the good MHC-I binders, the control-spe-
cific group had a very similar distribution to the common 
peptides, while the inhibitor-specific group had a lower 
percentage of 9mers and higher percentage of 10mers, 
11mers and 12mers (Fig. 4b). This trend was even more 
apparent when we considered peptides that were detected 
in both conditions but were either up-regulated or down-
regulated by the inhibitor (indicated in the boxed regions 
of Fig. 3b). For these peptides, the inhibitor reduced the 
percentage of 9mers from 75 to 50%, increased 10mers 
almost twofold, 11mers by tenfold, and 12mers by fivefold 
(Fig. 4c).
The inhibitor affected the average predicted affin-
ity of the identified peptides for MHC-I. The geometric 
mean of the predicted affinity for the common peptides 
was 138 nM, whereas for the control-specific peptides 
1808 nM and for the inhibitor-specific peptides 97 nM 
(Fig. 3c). Thus, it appears that upon inhibitor incubation, 
a subset of weak-binding peptides was substituted by more 
tightly binding peptides. This is a surprising result that 
suggests that ERAP1 has a strongly destructive function in 
this cell line. Many of the weak-binding peptides that are 
no longer detectable upon inhibitor incubation fall within 
the 12mer–16mer range. It should be noted, however, that 
affinity-prediction algorithms such as netMHCcons are not 
optimized for predicting affinity of longer peptides and 
thus the affinity of the 12–16mers in the control condition 
may be an underestimate and several good MHC-I ligands 
may exist in that subset [62]. Regardless, the inhibitor 
appears to eradicate many weakly binding 12–16mers and 
increase the representation of higher affinity 9–11mers.
Effects on peptide sequence
Given the enzymatic activity of ERAP1 as an aminopepti-
dase, we examined the effect of the inhibitors on the nature 
of the first amino acid of the presented peptides. It should be 
Fig. 4  The inhibitor affects the length of presented peptides. a Dis-
tribution of lengths of identified peptides per condition. b Same as in 
(a), but only for peptides predicted to bind to MHC-I with an affin-
ity of < 1 μM. c Distribution of lengths of peptides that are common 
to both conditions but either up-regulated or down-regulated by the 
inhibitor for greater than fourfold (as defined in Fig. 3b)
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noted that ERAP1 activity can in principle reduce or even 
eradicate the binding of peptides onto MHC-I and in this 
context all presented peptides carry amino acids at their N 
terminus that have escaped ERAP1-mediated trimming. 
Certain aspects of the mechanism that ERAP1 uses to trim 
peptides remain controversial and no consensus has been 
unequivocally reached on whether MHC-I binding is always 
protective from further trimming or can actually promote 
peptide degradation [63]. Analysis of the distribution of the 
first amino acid in the identified peptides showed that irre-
spective of the presence or absence of inhibitor all residues 
are represented, but to varying degrees (< 1 to 22%). Sig-
nificant differences between the control and inhibitor con-
ditions were evident. To visualize the changes induced by 
the inhibitor, we plotted the relative change of the inhibitor-
specific and control-specific peptides in comparison to the 
common peptides since these two groups should represent 
groups of peptides that are either destroyed by ERAP1 or 
require ERAP1 for generation, respectively (Fig. 5). Over-
all, inhibitor treatment increased the frequency of peptides 
carrying on their N terminus amino acids such as Tyr, Met, 
Leu and Ala, previously demonstrated to be optimal sub-
strates for ERAP1, and reduced the frequency of less optimal 
substrates carrying other N-terminal residues (Fig. 5a) [64]. 
This trend was clearer when we limited the analysis to pep-
tides predicted to be good MHC-I binders (Fig. 5b).
Of note is the strong effect of the inhibitor on peptides 
that carry an N-terminal Pro residue (233 peptides), which 
were virtually absent from the inhibitor-treated samples 
(Fig. 5a). This effect was not evident when limiting the 
analysis to good MHC-I binders, because virtually all of 
the peptides starting with a Pro residue were predicted to be 
poor MHC-I ligands (Fig. 5b). Furthermore, this phenom-
enon extends to peptides with Pro at position 2 (78 peptides) 
and to peptides that have an Asp residue at position − 1. 
Since, however, the Asp–Pro bond can be self-catalytically 
broken during acidic treatments that are part of the isolation 
protocol [65], it is possible that some of the Pro-starting 
peptides were originally Asp–Pro in the analyzed samples. 
All three groups of these peptides (311 peptides in total) 
were over-represented in the control samples (Supplemen-
tal Figure S5a), predicted to be weak MHC-I binders (Sup-
plemental Figure S5b), and of varied lengths (Figure S5c). 
Since ERAP1 cannot cleave peptides with Pro as the first 
or second residue [46], these peptides would be expected 
to be fully ERAP1 resistant and to accumulate to higher 
fractional levels with high ERAP1 activity. When ERAP1 
is inhibited, ERAP1-sensitive peptides that are good MHC-I 
binders may be spared and accumulate. Such peptides can 
out-compete the Pro-containing peptides and reduce their 
relative abundance. This finding would suggest that, at least 
in A375 cells, ERAP1 has a strong destructive influence on 
many optimal MHC-I epitopes.
To investigate possible effects of the inhibitor on the 
internal sequence motifs of presented peptides, we per-
formed Gibbs cluster analysis on the 9mer sequences of 
identified peptides in each set using the GibbsCluster-2.0 
Server and Seq2logo servers [66, 67] (Fig. 6). This server 
applies the Gibbs clustering algorithm to reveal peptide 
sequence motifs from large groups of peptides [68]. Since 
we are analyzing the immunopeptidome from cells that 
carry six different HLA alleles that have different bind-
ing preferences (Fig. 2), clustering results will encompass 
binding preferences from all alleles. Figure 6 presents the 
clustering results for the three most dominant clusters of 
each set. In all cases, a minimum of two positions dominate 
in sequence conservation, corresponding to anchor residues 
preferred by respective HLA alleles. A major cluster (Fig. 6, 
Fig. 5  Inhibitor treatment increases the abundance of peptides car-
rying N termini that are ERAP1 sensitive. a Distribution of the first 
amino acid of identified 9mer peptides in the control-specific and 
inhibitor-specific set, in comparison to the common peptides. b Same 
as in (a), but limited to the good MHC-I binders. Amino acids in the 
x-axis are ordered based on experimentally determined sensitivity to 
ERAP1 [64]
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top panels) contains peptides with hydrophobic residues at 
positions 2 and 9 and probably represents peptides presented 
by HLA-A*02:01 and to a lesser extent HLA-B*57:01 and 
HLA-C*16:01:01. A second major cluster (Fig. 6, middle 
panels) contains peptides that carry negatively charged and 
hydrophilic residues at position 2 and hydrophobic resi-
dues at position 9, presumably presented by HLA-B*44:03, 
HLA-B*57:01 and HLA-C*16:01. A third major cluster 
(Fig. 6, bottom panels) contains peptides with negatively 
charged amino acids at position 3 and hydrophobic amino 
acids at position 9, consistent with peptides presented by 
HLA-A*01:01. HLA-C*06:02 does not appear in a sepa-
rate cluster possibly due to lack of a clear anchor residue in 
the first few positions, but is probably included in all three 
clusters since it prefers peptides with hydrophobic residues 
at position 9. Overall, the patterns revealed by cluster analy-
sis suggest that the HLA binding preferences are dominant 
in selecting the majority of peptides presented, irrespective 
of ERAP1 activity, although ERAP1 activity can influence 
which peptides are presented within the constraints of the 
MHC-I binding preferences. Some increased heterogeneity 
is evident in the inhibitor-specific set, which features slightly 
reduced sequence conservation scores. This may be inter-
esting immunologically in the context of the presentation 
of novel peptides that can induce  CD8+ responses, which 
would be increased upon ERAP1 inhibition.
Discussion
ERAP1 inhibition does not abrogate 
presentation and has a significant effect 
on the immunopeptidome
Initial studies on the effects of ERAP1 down-regulation 
using siRNA in HeLa cells had suggested that it can sig-
nificantly impact total cell-surface MHC-I presence [18, 
54, 69]. Later studies have focused more on the cargo of 
MHC-I and often did not show significant effects on total 
expression of MHC-I on the cell surface, hinting that such 
phenomena may be dependent on the combination of HLA 
alleles and cell line [25, 41, 50, 57]. In our system, we find 
Fig. 6  Inhibitor treatment does not affect the basic sequence motifs of presented peptides. Gibbs cluster analysis of 9mer sequences of identified 
peptides. Analysis was performed using the GibbsCluster-2.0 Server and plotted using the Seq2logo server [66, 67]
1256 Cancer Immunology, Immunotherapy (2019) 68:1245–1261
1 3
no evidence of significant down-regulation of cell-surface 
MHC-I levels by a potent ERAP1 inhibitor. This may be 
due to either ERAP1 not significantly affecting the levels of 
available peptides, or to peptide supply not being a limiting 
factor for MHC-I presence on the cell surface. Indeed, in a 
recent study, the authors demonstrated that MHC-I levels 
are dependent on the availability of receptive MHC-I rather 
than peptide supply, a mechanism that may also apply on 
our system [70]. Regardless of the mechanism, alteration of 
the MHC-I immunopeptidome without significant alteration 
of overall surface expression level may be highly desirable 
pharmacologically since down-regulation of MHC-I levels 
is a common immune evasion strategy by tumors [71, 72]. 
Our findings suggest that chemically inhibiting ERAP1 can 
induce significant changes in the immunopeptidome without 
abrogating antigen presentation.
The overall changes in the immunopeptidome induced 
by the ERAP1 inhibitor are modest as approximately half 
of the peptides presented and two-thirds of the predicted 
good MHC-I binders are not affected. Although this might 
potentially be due to incomplete inhibition of ERAP1, we 
think that explanation is unlikely because of the large effect 
observed in a cell-based presentation assay for a known 
ERAP1-dependent epitope, and since previous studies 
using transgenic animals (discussed in more detail below) 
also have demonstrated that a significant component of the 
immunopeptidome is ERAP1-independent [25, 57]. Even 
modest changes to the immunopeptidome, however, can 
result in drastic changes in cytotoxic responses by alter-
ing immunodominance [19, 20, 24]. The limited effects of 
ERAP1 inhibition on MHC-I expression level and modest 
alteration of the immunopeptidome actually may be ben-
eficial on a therapeutic setting since this would help avoid 
undesirable side effects by overactivating immune responses.
The dual role of ERAP1 in generating and destroying 
peptides
Soon after the first discovery of ERAP1, several studies had 
hinted at a complex landscape regarding its effects on MHC-
I-presented peptides. RNA interference of ERAP1 or its 
close mouse homologue ERAAP was shown to affect cell-
surface MHC-I levels and to specifically enhance MHC-I 
levels in baseline cell culture but to reduce MHC-I levels 
in cells treated with interferon-gamma (a cytokine known 
to enhance overall antigen presentation by increasing the 
expression of several proteins in the antigen presentation 
pathway, including ERAP1 [18, 54, 69]). These and sub-
sequent studies suggested that ERAP1 can either destroy 
or generate peptide cargo for MHC-I, depending on other 
factors, including its own expression levels, MHC-I expres-
sion levels, availability of peptides in the ER, and peptide 
sequence. Further studies have validated this initial notion 
and have highlighted ERAP1 as an MHC-I cargo editor [20, 
73]. The results presented here on the effects of pharmaco-
logical inhibition of ERAP1 on the immunopeptidome of 
melanoma cells are consistent with this notion. Chemical 
inhibition of ERAP1 shifts part of the immunopeptidome 
without abrogating overall MHC-I presentation. It is, how-
ever, surprising that in our model system ERAP1 inhibi-
tion appears to induce the presentation of many MHC-I-
optimized peptides, consistent with a baseline destructive 
role of ERAP1. This finding, however, does correlate with 
a proposed role of ERAP1 in tumor cell immune evasion: 
ERAP1 can be up-regulated [37] to destroy tumor-specific 
antigens to facilitate immune evasion of  CD8+- or NK-medi-
ated cytotoxic responses. Specifically for melanoma, recent 
work has shown that ERAP1 can destroy a potent tumor-
associated antigenic peptide and ERAP1 down-regulation 
can enhance anti-tumor cytotoxicity and anti-PD-1 immuno-
therapy [10, 39]. Our work here suggests that chemical inhi-
bition of ERAP1 can affect the presentation of hundreds to 
thousands of peptides, effectively inducing antigenic shifts 
that increase the chances that an immune-evading tumor will 
be recognized by the immune system.
Studies on the immunopeptidome of other cell lines 
and transgenic animals
The effects of ERAP1 on the immunopeptidome have been 
studied in several human cell lines [34, 50, 74]. In those 
studies, the authors compared the immunopeptidome pre-
sented by particular HLA alleles (namely HLA-B*27, HLA-
A*29:02, HLA-B*51) from cell lines expressing alleles of 
ERAP1 that have different activity and selectivity [32, 35]. 
Detailed proteomic analysis demonstrated effects of differ-
ential ERAP1 activity on antigen presentation and supported 
the role of ERAP1 haplotypes on HLA-associated inflam-
matory autoimmunity (reviewed in [27]). Overall, these pre-
vious studies had suggested that ERAP1 affects a fraction 
of the peptidome and that its down-regulation can lead to 
increased frequency of longer peptides and can affect the 
nature of the first amino acid, all effects consistent with a 
productive role of ERAP1. Significant knowledge on the 
biology of ERAP1 has been derived from animal studies. 
Most of those studies have focused on the effect of ERAP1 
knockout (eraap−/−) on immunodominance and immuno-
genicity, and have described strong, albeit variable, effects 
on both these areas [19, 20, 24]. Two recent studies have 
performed deep proteomic analysis of the effects of ERAP1 
deletion on knockout animals. In one study, the authors ana-
lyzed the peptidome of HLA-B27 transgenic rats and found 
that ERAP1 deletion affected only a subset of the peptidome 
with additional effects on peptide length and sequence [25]. 
In another study, the authors analyzed the effects of ERAP1 
deletion on the immunopeptidome of bone marrow-derived 
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dendritic cells of transgenic mice, and described strong 
shifts in both sequence and length [57]. Overall the effects 
of the ERAP1 inhibitor on the melanoma cell line described 
here are consistent with the effects described in other cell 
lines and transgenic/knockout animals—namely changes 
restricted to a subset of the peptidome, including effects 
on peptide length and sequence. It is notable, however, that 
in our system, chemical ERAP1 inhibition also appears to 
eradicate a subset of elongated peptides with poor affinity 
for MHC-I that are resistant to ERAP1 trimming primarily 
due to the presence of a Pro residue at position 1 or 2 of the 
sequence. Furthermore, ERAP1 inhibition leads to the gen-
eration of hundreds of new and affinity-optimized MHC-I 
ligands that include peptides between 10–12 amino acids 
long that potentially can be immunogenic. This phenomenon 
is consistent with a baseline destructive effect of ERAP1 in 
this cell line and fits well with previous observations that 
ERAP1 can destroy an immunogenic epitope in another 
melanoma cell line [39], and that its activity can promote 
immune evasion [28, 37]. While this effect may be cell line 
specific, it provides support to the hypothesis that ERAP1 
inhibition in cancer may promote immunogenicity [75].
Chemical versus genetic down‑regulation of ERAP1 
activity
An additional issue to consider when comparing genetic 
to pharmacological approaches, especially in the context 
of antigen processing and presentation, is the kinetics of 
the system. Antigen processing and presentation is a highly 
dynamic competitive system in which many different anti-
gens compete for few positions on the MHC at the cell sur-
face. Short-term chemical inhibition may not be able to fully 
reproduce permanent genetic changes in cells due to this 
kinetic component. Furthermore, all inhibitors, regardless of 
their known specificity, may have off-target effects, which, 
even if they are outside the biochemical pathway targeted, 
may still affect antigen presentation by altering the cellular 
proteome. Regardless of this complication, evaluating the 
effects of ERAP1 inhibition by chemical compounds is a 
prerequisite to any pre-clinical development of compounds 
with pharmaceutical interest and central to the development 
of therapeutic applications. Furthermore, in vivo genetic 
down-regulation model systems (i.e. ,knockout animals) 
may be of limited value in predicting the effects of chemi-
cal inhibition for at least two main reasons: i) differences in 
the gene components of the pathway between humans and 
experimental animals, which are quite common for com-
ponents of immune system pathways, and ii) modifications 
and adjustments of the cellular proteome and presentation 
during the generation of tolerance and among different cell 
lines. Regardless of these limitations, treating the A375 
melanoma cell line with the DG013A inhibitor does appear 
to reproduce the effects that would be expected from ERAP1 
activity down-regulation, and supports the main hypothesis 
that using an ERAP1 inhibitor is a valid approach for manip-
ulating the immunopeptidome of cells without generating 
any major defects in the quality of antigen presentation.
Potential impact on anti‑cancer responses: 
limitations of the study
While the results described in this study hint to possi-
ble alterations of the immunogenicity of melanoma upon 
treatment with the inhibitor in vivo, key limitations of the 
scope of this study need to be acknowledged to avoid over-
interpretation. Indeed, the finding that the inhibitor induces 
the presentation of many new MHC-I presented peptides 
could raise hopes regarding the therapeutic potential of 
this approach in enhancing the immunogenicity of can-
cer. However, this would be speculative at this point since 
immunogenicity and anti-tumor responses were not exam-
ined. Furthermore, potential off-target and off-function side 
effects could complicate interpretation of results as well as 
therapeutic applications. Indeed, DG013A is not selective 
versus the highly homologous enzyme ERAP2, which, how-
ever, has more limited effects in antigen presentation and 
is poorly expressed in A375 cells. Regardless, the lack of 
selectivity of DG013A versus homologous aminopeptidases 
is a limiting factor for clinical development. Furthermore, 
ERAP1 has been reported to have other functions that could 
complicate therapeutic approaches and are not examined 
here (reviewed in [76]). More specifically, reports have 
demonstrated ERAP1 involvement in other aspects of the 
immune response, in particular cytokine receptor shedding 
and macrophage activation [77, 78]. Additionally, although 
inhibitor treatment generated novel MHC-I ligands, it also 
abrogated many, suggesting that it could be detrimental to 
some existing anti-tumor immune responses. Given, how-
ever, that most cancers develop immune evasion [79], the 
generation of novel antigenic peptides may outweigh the 
destruction of some existing ones. Further studies are nec-
essary to address these potential caveats and to explore in 
more detail the global effects of ERAP1 inhibition on the 
immune system.
Although ERAP1 inhibition may bring about desirable 
shifts in the immunopeptidome of cancer cells, systemic 
delivery will likely induce immunopeptidome shifts in nor-
mal cells as well, raising concerns that about induction of 
autoimmune-like responses. While these effects certainly are 
undesirable, they may be tolerable, not unlike the situation 
with immune-checkpoint inhibitor therapy approaches that 
can also target normal cells and present serious side effects, 
yet are successful clinically. Immunogenicity requires the 
coordination of several signals, of which antigen pres-
entation is only one. As a result, reprogramming antigen 
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presentation may shift the balance towards new immune 
responses only in systems that are immunogenic to begin 
with. Indeed, it has been shown previously that cytomeg-
alovirus induces infected cells to down-regulate ERAP1 
expression via a particular microRNA as part at its immune 
evasion strategy [36]. While these infections are common in 
the population, no association between human CMV infec-
tion and autoimmunity has been demonstrated, an observa-
tion that suggests that lowering ERAP1 activity could have 
a rather minor effect on the immunogenicity of healthy cells.
Pharmacological applications for enhancing 
immunogenicity of cancer
In summary, we present here a detailed HLA peptidomics 
analysis of how the immunopeptidome of the A375 mela-
noma cell line is regulated by a potent ERAP1 inhibitor. We 
find that the inhibitor affects about half of the immunopep-
tidome and a third of the good MHC-I ligands, and induces 
the presentation of many peptides that are predicted to be 
optimal ligands for MHC-I. Our results suggest significant 
target engagement by the inhibitor and are consistent with 
the known biology of ERAP1 as accumulated by genetic 
down-regulation and functional studies. However, our results 
also highlight some key differences from previous stud-
ies, which may be the result of the transient nature of the 
inhibition or from off-target effects that need to be further 
evaluated. This is the first study, to our knowledge, that has 
explored the use of a particular inhibitor to induce short-
term ERAP1-dependent immunopeptidome shifts. Further-
more, our results suggest that ERAP1 activity in melanoma 
is important for shaping a part of the final MHC-I peptide 
repertoire and may be exploitable for enhancing immu-
nogenicity. Given the current interest in enhancing tumor 
antigenicity for cancer immunotherapy, our results provide 
experimental support that ERAP1 inhibition can constitute 
a promising approach towards that goal. This may be espe-
cially true for supplementing immune-checkpoint inhibitor 
immunotherapy as recently demonstrated in a melanoma 
mouse tumor model in which genetic ERAP1 depletion 
increased the efficacy of anti-PD-1 immunotherapy [10]. 
Future studies will undoubtedly have to focus on exploring 
the applicability of these pharmacologically induced immu-
nopeptidome shifts to enhancing anti-cancer or suppressing 
auto-inflammatory immune responses in relevant ex vivo or 
animal models.
Data deposition
The mass spectrometry data have been deposited to the Pro-
teomeXchange Consortium via the PRIDE partner repository 
with the dataset identifier PXD011766. A MaxQuant style 
table listing all identified peptides and relevant parameters can 
be downloaded at https ://sfile r.ipta.demok ritos .gr/s/qMJGB 
CCE6o Sqi5p using as password erap1a375.
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